{"id":"shpl-49-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing the immune response against cancer cells.","oneSentence":"SHPL-49 Injection is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:25.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07241520","phase":"PHASE3","title":"Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Shanghai Hutchison Pharmaceuticals Limited","startDate":"2025-12-08","conditions":"Acute Ischemic Stroke","enrollment":1096},{"nctId":"NCT06202378","phase":"PHASE2","title":"Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Shanghai Hutchison Pharmaceuticals Limited","startDate":"2023-12-29","conditions":"Acute Ischemic Stroke","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHPL-49 Injection","genericName":"SHPL-49 Injection","companyName":"Shanghai Hutchison Pharmaceuticals Limited","companyId":"shanghai-hutchison-pharmaceuticals-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHPL-49 Injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}